Drugs / FF-3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02423577 | Sep 2015 → Jun 2016 | influenza | Autoimmune Technologies, LLC | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FF-3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02423577 ↗ |
| Route | Intranasal | “FF-3 dry powder administered by nasal inhalation” NCT02423577 ↗ |